The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...

Radiopharm Theranostics Ltd (ASX:RAD) has received approval from the Australian Ethics Committee to expand its trial to ...

how a protein capable of preventing programmed cell death can also promote it. Their study, led by Robert Horvitz, the David ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later ...

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...